Mr. Mazzo will serve as chief executive of AcuFocus, a company in Versant’s portfolio. He will help the firm expand its ophthalmology-related opportunities.
Versant Ventures is a venture capital firm with investments in medical devices, biopharmaceuticals and life science technologies. The firm has heavily invested in eye condition treatments.
More Articles on Ophthalmology:
Gordon-Weiss-Schanzlin Vision Institute Eye Surgeons Perform New LASIK Surgery
Bausch + Lomb Acquires Developmental Agent to Treat Dry Eye Syndrome
University of Oklahoma’s Dean McGee Eye Institute Receives $110k Grant from Research to Prevent Blindness
